ImmunityBio, Inc.
IBRX
$7.80
-$0.26-3.21%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 193.98% | 358.72% | 696.21% | 1,050.02% | 4,383.61% |
| Total Other Revenue | 76.67% | -40.14% | -48.57% | 64.69% | 60.38% |
| Total Revenue | 192.92% | 351.53% | 668.31% | 1,025.95% | 4,227.22% |
| Cost of Revenue | 464.43% | 1,508.62% | -- | -- | -- |
| Gross Profit | 191.98% | 349.38% | 663.21% | 1,020.89% | 4,212.39% |
| SG&A Expenses | 13.28% | 1.62% | -12.33% | -8.36% | -6.37% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 22.11% | 16.75% | 2.89% | -6.36% | -5.13% |
| Operating Income | 11.76% | 16.60% | 25.61% | 27.43% | 20.55% |
| Income Before Tax | -170.36% | -108.71% | 15.00% | 40.69% | 38.59% |
| Income Tax Expenses | -560.00% | 146.15% | -- | 100.00% | 187.50% |
| Earnings from Continuing Operations | -170.29% | -108.86% | 15.03% | 40.69% | 38.58% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -21.52% | -13.75% | -8.64% | -10.47% | -35.77% |
| Net Income | -170.33% | -108.88% | 15.03% | 40.69% | 38.58% |
| EBIT | 11.76% | 16.60% | 25.61% | 27.43% | 20.55% |
| EBITDA | 12.55% | 17.25% | 26.34% | 28.23% | 21.11% |
| EPS Basic | -110.65% | -54.77% | 34.94% | 52.95% | 50.82% |
| Normalized Basic EPS | -109.59% | -53.63% | 34.85% | 52.87% | 50.74% |
| EPS Diluted | -96.71% | -45.15% | 38.67% | 52.96% | 47.67% |
| Normalized Diluted EPS | -109.80% | -53.76% | 34.80% | 52.87% | 50.79% |
| Average Basic Shares Outstanding | 26.58% | 29.71% | 31.87% | 25.54% | 25.43% |
| Average Diluted Shares Outstanding | 26.45% | 29.56% | 31.71% | 25.49% | 25.56% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |